BioSpace News Archive

Financing will support i20 Therapeutics’ growth and R&D of platform for oral delivery of injectable biologic drugs

Riptide Bioscience, Inc., today announced that Dame Carol M. Black, FRCP, MACP, FMedSci, Foreign Associate Member of the Institute of Medicine USA, renowned clinician/scientist and eminent expert in systemic sclerosis, has joined the company’s Scientific Advisory Board (SAB).

DiaCarta Inc, a precision molecular diagnostic company in CA, announced Thursday the US FDA granted Emergency Use Authorization for DiaCarta’s proprietary QuantiVirus™ PCR diagnostic (Dx) test specifically detecting three different genes of SARS-CoV-2, the virus causing the COVID-19 pandemic. DiaCarta recently expanded manufacturing capacity to 500,000 tests per week and is planning to expand to even larger (4x) scale m

Sangamo has received $225 million in stock proceeds; will receive additional $125 million upfront license fee by May 8, 2020

Vicromax shown to decrease viral production of Covid -19 coronavirus by over 98% Article highlights recent work done in laboratory studies of Covid -19 with Vicromax(tm) at the Galveston Lational Laboratory at The University of Texas Medical Branch BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announce

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that a regulatory submission has been made to the Ministry of Food and Drug Safety in South Korea for an investigator-led Phase 2 COVID-19 study of its re-purposed drug NP-120 (Ifenprodil).

Xyntek Inc, is proud to announce that it is entering into a new era, announcing a new company structure under the name CXV Global Ltd. This agreement will now bring together three long-time partner companies ( Crest Solutions , Xyntek and VistaLink) under the umbrella name of CXV Global to create a single source solution g

ReAlta Life Sciences, Inc., a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform to address life-threatening medical needs, today announced that it has appointed Jonathan Zalevsky, Ph.D., an immunology expert, and Christine Neikirk, a governance and marketing expert, to its board of directors.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has acquired Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cells. Terms of the acquisition were not disclosed. Bio-Rad will discuss the acquisition in more detail during its first-quarter 2020 fina

Laurent Pharmaceuticals to initiate world-first testing of LAU-7b in COVID-19 patients